147 related articles for article (PubMed ID: 24872129)
1. Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent.
Meier SM; Novak MS; Kandioller W; Jakupec MA; Roller A; Keppler BK; Hartinger CG
Dalton Trans; 2014 Jul; 43(26):9851-5. PubMed ID: 24872129
[TBL] [Abstract][Full Text] [Related]
2. Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
Kandioller W; Hartinger CG; Nazarov AA; Bartel C; Skocic M; Jakupec MA; Arion VB; Keppler BK
Chemistry; 2009 Nov; 15(45):12283-91. PubMed ID: 19821465
[TBL] [Abstract][Full Text] [Related]
3. Design of Ru-arene Complexes for Antitumor Drugs.
Su W; Li Y; Li P
Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
[TBL] [Abstract][Full Text] [Related]
4. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
5. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.
Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V
Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087
[TBL] [Abstract][Full Text] [Related]
6. Selective cytotoxic Ru(II) arene Cp* complex salts [R-PhRuCp*](+)X(-) for X = BF4(-), PF6(-), and BPh4(-).
Loughrey BT; Healy PC; Parsons PG; Williams ML
Inorg Chem; 2008 Oct; 47(19):8589-91. PubMed ID: 18783214
[TBL] [Abstract][Full Text] [Related]
7. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
8. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes.
Yan YK; Melchart M; Habtemariam A; Sadler PJ
Chem Commun (Camb); 2005 Oct; (38):4764-76. PubMed ID: 16193110
[TBL] [Abstract][Full Text] [Related]
9. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
10. Phosphoramidate protides of five flavones and their antiproliferative activity against HepG2 and L-O2 cell lines.
Li YQ; Yang F; Wang L; Cao Z; Han TJ; Duan ZA; Li Z; Zhao WJ
Eur J Med Chem; 2016 Apr; 112():196-208. PubMed ID: 26896708
[TBL] [Abstract][Full Text] [Related]
11. Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity.
Bratsos I; Jedner S; Bergamo A; Sava G; Gianferrara T; Zangrando E; Alessio E
J Inorg Biochem; 2008; 102(5-6):1120-33. PubMed ID: 18279961
[TBL] [Abstract][Full Text] [Related]
12. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
[TBL] [Abstract][Full Text] [Related]
13. Novel tetranuclear ruthenium(II) arene complexes showing potent cytotoxic and antimetastatic activity as well as low toxicity in vivo.
Mohamed Subarkhan MK; Ren L; Xie B; Chen C; Wang Y; Wang H
Eur J Med Chem; 2019 Oct; 179():246-256. PubMed ID: 31255925
[TBL] [Abstract][Full Text] [Related]
14. Anticancer activity of tetracationic arene ruthenium metalla-cycles.
Barry NP; Edafe F; Therrien B
Dalton Trans; 2011 Jul; 40(27):7172-80. PubMed ID: 21660364
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, visible light photocleavage, antiproliferative and cellular uptake properties of ruthenium complex [Ru(phen)2(mitatp)]2+.
Yu HJ; Chen Y; Yu L; Hao ZF; Zhou LH
Eur J Med Chem; 2012 Sep; 55():146-54. PubMed ID: 22841281
[TBL] [Abstract][Full Text] [Related]
16. Lipophilicity-antiproliferative activity relationship study leads to the preparation of a ruthenium(II) arene complex with considerable in vitro cytotoxicity against cancer cells and a lower in vivo toxicity in zebrafish embryos than clinically approved cis-platin.
Haghdoost M; Golbaghi G; Létourneau M; Patten SA; Castonguay A
Eur J Med Chem; 2017 May; 132():282-293. PubMed ID: 28371640
[TBL] [Abstract][Full Text] [Related]
17. Library of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier.
Fetzer L; Boff B; Ali M; Xiangjun M; Collin JP; Sirlin C; Gaiddon C; Pfeffer M
Dalton Trans; 2011 Sep; 40(35):8869-78. PubMed ID: 21837342
[TBL] [Abstract][Full Text] [Related]
18. Anticancer potency studies of coordination driven self-assembled arene–Ru-based metalla-bowls.
Mishra A; Jeong YJ; Jo JH; Kang SC; Lah MS; Chi KW
Chembiochem; 2014 Mar; 15(5):695-700. PubMed ID: 24677392
[TBL] [Abstract][Full Text] [Related]
19. Labile ruthenium(ii) complexes with extended phenyl-substituted terpyridyl ligands: synthesis, aquation and anticancer evaluation.
Huang H; Zhang P; Chen Y; Ji L; Chao H
Dalton Trans; 2015 Sep; 44(35):15602-10. PubMed ID: 26245234
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a dual-targeting organometallic ruthenium complex with high activity inducing early stage apoptosis of cancer cells.
Du J; Zhang E; Zhao Y; Zheng W; Zhang Y; Lin Y; Wang Z; Luo Q; Wu K; Wang F
Metallomics; 2015 Dec; 7(12):1573-83. PubMed ID: 26446567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
